CIPLA
Cipla Limited (CIPLA) Stock Analysis
Cipla Limited is one of India's largest pharmaceutical companies with global reach. It manufactures respiratory, HIV, oncology, and generic medicines for domestic and export markets. Hospitals, pharmacies, and governments are major customers worldwide. The company is listed on Indian stock exchanges and is headquartered in India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,301.00
-3.20% 1W | -16.30% 52W
Market Cap
105.1k CR
P/E Ratio
31.2
52W High
₹1673
52W Low
₹1165.7
Div. Yield
0.99%
Beta
0.1
50 DMA
₹1403.6
200 DMA
₹1367.8
Profit Margin
12%
Inst. Own.
44.8%
⚡ APPROACHING SUPPORT
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,329 | 6,678 | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Expenses | 4,835 | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 |
| Operating Profit | 1,494 | 1,734 | 1,748 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 |
| OPM % | 24% | 26% | 26% | 21% | 26% | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% |
| Other Income | 136 | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 |
| Interest | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 |
| Depreciation | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 |
| Profit before tax | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 |
| Tax % | 28% | 28% | 28% | 26% | 27% | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% |
| Net Profit | 998 | 1,155 | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| EPS in Rs | 12.33 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,345 | 13,790 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 | 28,324 |
| Expenses | 9,183 | 11,310 | 11,898 | 12,329 | 13,265 | 13,926 | 14,907 | 17,211 | 17,726 | 19,483 | 20,420 | 22,280 | 23,027 |
| Operating Profit | 2,163 | 2,480 | 2,496 | 2,826 | 3,097 | 3,206 | 4,252 | 4,553 | 5,027 | 6,291 | 7,128 | 5,883 | 5,297 |
| OPM % | 19% | 18% | 17% | 19% | 19% | 19% | 22% | 21% | 22% | 24% | 26% | 21% | 19% |
| Other Income | 164 | 208 | 208 | 280 | 477 | 344 | 266 | 99 | 293 | 552 | 862 | 606 | 558 |
| Interest | 168 | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 62 | 54 | 57 |
| Depreciation | 505 | 754 | 1,323 | 1,323 | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,051 | 1,107 | 1,211 | 1,262 |
| Profit before tax | 1,654 | 1,727 | 1,222 | 1,669 | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 5,702 | 6,821 | 5,224 | 4,536 |
| Tax % | 24% | 19% | 15% | 15% | 27% | 29% | 27% | 27% | 30% | 27% | 22% | 26% | |
| Net Profit | 1,229 | 1,383 | 1,035 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 | 3,356 |
| EPS in Rs | 14.71 | 16.93 | 12.51 | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 51.05 | 65.28 | 48.02 | 41.74 |
| Dividend Payout % | 14% | 12% | 16% | 17% | 16% | 21% | 17% | 16% | 24% | 25% | 25% | 27% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 8.0% | 7.0% |
| Profit CAGR | 10.0% | 10.0% | 11.0% |
Shareholding Pattern
Promoters29.19%
FIIs25.24%
DIIs28.98%
Public16.30%
Promoters29.22%
FIIs24.54%
DIIs29.98%
Public15.99%
Promoters29.22%
FIIs23.93%
DIIs30.45%
Public16.12%
Promoters29.22%
FIIs22.55%
DIIs31.71%
Public16.26%
Promoters29.22%
FIIs20.20%
DIIs34.35%
Public15.93%
Promoters33.55%
FIIs27.42%
DIIs21.83%
Public16.99%
Promoters33.46%
FIIs25.82%
DIIs24.15%
Public16.36%
Promoters29.20%
FIIs26.28%
DIIs27.89%
Public16.36%
Promoters29.22%
FIIs22.55%
DIIs31.71%
Public16.26%
Promoters29.22%
FIIs20.20%
DIIs34.35%
Public15.93%
CIPLA
Holdings Analysis
Key strengths & risk signals
60
Overall
68
Fundamental
52
Technical
Risks (4)
NEGLIGIBLE DIVIDEND! 0.99% yield - little to no income.
WEAK POSITION! Current price (1301.0) is below both moving averages.
WEAK YEAR! Stock declined 16.3% in the last year.
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.2% (1 week), 4.6% (1 month), 9.6% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1403.6) is above 200-day average (1367.8) - positive signal.
OVERSOLD! RSI at 26.8 - potential bounce opportunity.
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
Fundamental & Technical Analysis
60Overall
68Fundamental
52Technical
Fundamental Breakdown
Growth Quality
19/30
Revenue CAGR: 7.2% (MODERATE, 8/15). Profit CAGR: 11.5% (GOOD, 11/15).
Profit Margin
5/10
DECENT EFFICIENCY! 12.0% profit margin - acceptable profitability.
PEG Valuation
5/10
OVERVALUED! PEG of 2.71 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.99% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.01 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 16.76% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (1403.6) is above 200-day average (1367.8) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (1301.0) is below both moving averages.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
2/10
WEAK YEAR! Stock declined 16.3% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 870,526 vs down days: 921,746. Ratio: 0.94x
RSI
5/5
OVERSOLD! RSI at 26.8 - potential bounce opportunity.
52W Range
2/5
LOWER HALF! Trading at 26.7% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.2% (1 week), 4.6% (1 month), 9.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
CIPLA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-07-27 | Concall PDF | |
| Q4FY262026-07-04 | Concall PDF | |
| Q2FY262026-01-27 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CIPLA | ₹1,301.00 | 31.2 | 12.0% | 7.2% | 11.5% | -16.3% | 60 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| LAURUSLABS | ₹2,036.60 | 100.7 | 15.0% | 3.8% | 4.0% | +127.9% | 55 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| DRREDDY | ₹1,197.00 | 30.1 | 10.0% | 11.0% | -1.7% | -3.4% | 63 | BREAKOUT | -68.7% | +100.8% | -5.6% | +7.4% |
| ZYDUSLIFE | ₹1,117.50 | 24.9 | 15.8% | 16.5% | 37.0% | +15.9% | 75 | APPROACHING SUPPORT | -35.9% | -26.1% | +20.6% | +4.9% |
| MANKIND | ₹2,368.50 | 47.9 | 13.9% | 17.7% | 14.3% | -3.2% | 70 | APPROACHING SUPPORT | +29.6% | +2.5% | +12.9% | +17.1% |
| AUROPHARMA | ₹1,693.00 | 26.5 | 10.6% | 10.7% | 22.1% | +45.5% | 81 | APPROACHING RESISTANCE | +25.2% | +12.1% | +16.9% | +4.0% |
| LUPIN | ₹1,956.50 | 16.2 | 18.5% | 19.1% | 131.5% | -1.1% | 65 | BREAKDOWN | +16.1% | -3.1% | +33.3% | +11.2% |
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
Data from TradeAlone · Updated daily
CIPLA News
Cipla Limited (cipla) Announces Exclusive Partnership with Qilu Pharmaceutical for Biosimilar Licensing2026-09-03Cipla Limited (NSE: Cipla) Secures Exclusive Licensing Agreement for Potential Best-in-class HER2 Bispecific ADC2026-08-31Cipla Limited (cipla) Q1fy27: Highest-ever Quarterly Revenue and Strong Market Performance2026-07-23Cipla Limited Q4 FY26 Results: Strong Growth Across Segments2026-05-13
